Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

piam farmaceutici s.p.a. - melatonina - melatonina

Европейски съюз - италиански - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonina - sleep initiation and maintenance disorders - psicolettici - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

avara liscate pharmaceutical services s.p.a. - tiopentale sodico - tiopentale sodico

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

piam farmaceutici s.p.a. - bacampicillina - bacampicillina

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

new research s.r.l. - bacampicillina - bacampicillina

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - bacampicillina - bacampicillina

Европейски съюз - италиански - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologici - lucentis è indicato negli adulti per:il trattamento di neovascolare (bagnato) degenerazione maculare legata all'età (amd), il trattamento delle disabilità visiva a causa di coroideale neovascularisation (cnv)il trattamento della disabilità visiva a causa di edema maculare diabetico (dme)il trattamento della disabilità visiva a causa di edema maculare secondario a occlusione della vena retinica (ramo rvo centrale o rvo).

Европейски съюз - италиански - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologici - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Европейски съюз - италиански - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Европейски съюз - италиански - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).